COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs

OBJECTIVES: We aimed to investigate the role of rheumatoid arthritis (RA) with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) exposure in COVID-19 outcomes. METHODS: Our study retrieved data from the US Collaborative Network in TriNetX between 1 January 2018 and 31...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Jih-Jin, Liu, Li-Teh, Chen, Chun-Hong, Chen, Liang-Jen, Wang, Shiow-Ing, Wei, James Cheng-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364175/
https://www.ncbi.nlm.nih.gov/pubmed/37479495
http://dx.doi.org/10.1136/rmdopen-2023-003038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364175/
https://www.ncbi.nlm.nih.gov/pubmed/37479495
http://dx.doi.org/10.1136/rmdopen-2023-003038

Ejemplares similares